eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability

Casacuberta-Serra, Sílvia; González-Larreategui, Íñigo; Soucek, Laura

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Casacuberta-Serra, Sílvia
dc.contributor.author	González-Larreategui, Íñigo
dc.contributor.author	Soucek, Laura
dc.date.accessioned	2024-01-17T10:29:19Z
dc.date.available	2024-01-17T10:29:19Z
dc.date.issued	2023-12-26
dc.identifier.citation	Casacuberta-Serra S, Gonzalez-Larreategui I, Soucek L. eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability. Transl Lung Cancer Res. 2023 Dec 26;12(12):2570–5.
dc.identifier.issn	2218-6751
dc.identifier.uri	https://hdl.handle.net/11351/10875
dc.description	MYC; Càncer de pulmó de cèl·lules no petites
dc.description.sponsorship	The authors received funding support by the “Proyectos de I+D+i en Líneas Estratégicas” (PLEC2021-007959) grant from the Spanish Ministry of Economy and Competitiveness; La Marató TV3 grant [2019429]; and the 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant. I.G.L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812). Authors from VHIO acknowledge the State Agency for Research (Agencia Estatal de Investigación) the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033).
dc.language.iso	eng
dc.publisher	AME Publishing
dc.relation.ispartofseries	Translational Lung Cancer Research;12(12)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Pulmons - Càncer - Tractament
dc.subject	Anomalies cromosòmiques
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	/drug therapy
dc.subject.mesh	Mutation
dc.title	eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.21037/tlcr-23-682
dc.subject.decs	carcinoma de pulmón de células no pequeñas
dc.subject.decs	/farmacoterapia
dc.subject.decs	mutación
dc.relation.publishversion	https://doi.org/10.21037/tlcr-23-682
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Casacuberta-Serra] Peptomyc S.L., Barcelona, Spain. [Gonzalez-Larreategui I] Models of Cancer Therapies Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Soucek L] Peptomyc S.L., Barcelona, Spain. Models of Cancer Therapies Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid	38205207
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/FPU20%2F04812
dc.rights.accessrights	info:eu-repo/semantics/openAccess